A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Eisai Inc.
Novartis
Taproot Health
Carisma Therapeutics Inc
Pfizer
Morphotek
Novartis
Daiichi Sankyo
Novartis
Santa Maria Biotherapeutics
Imunon
Novartis
Celldex Therapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb